Kit, device and method for detecting prostate cancer

Patent metadata

Field	Value
Publication number	US-11905565-B2
Application number	US-202217988959-A
Country	US
Kind code	B2
Filing date	Nov 17, 2022
Priority date	Aug 10, 2018
Publication date	Feb 20, 2024
Grant date	Feb 20, 2024

Abstract

This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.

First claim

The invention claimed is:

1. A method for detecting prostate cancer and then treating or performing a diagnostic procedure in a human subject, comprising:
measuring an expression level of hsa-miR-1185-2-3p in a blood, serum, or plasma sample from the subject;
comparing the measured expression level of hsa-miR-1185-2-3p to a control expression level in a sample from a healthy subject; and
detecting an increased level of hsa-miR-1185-2-3p in the sample from the subject as compared to the control expression level from the sample from the healthy subject;
wherein the increased level of hsa-miR-1185-2-3p indicates that the subject has prostate cancer;
and further treating the subject for the prostate cancer or performing a diagnostic procedure on the subject with the prostate cancer;
wherein the treating comprises surgery, radiotherapy, chemotherapy or a combination thereof; and
wherein the diagnostic procedure comprises rectal examination, transrectal ultrasonography of the prostate, or imaging of prostate tissue.

2. The method according to claim 1 comprising: plugging the gene expression level of hsa-miR-1185-2-3p in the sample from the subject into a discriminant formula capable of discriminating the presence or absence of prostate cancer distinctively, wherein the discriminant formula is created using gene expression levels in samples from subjects known to have prostate cancer and gene expression levels in samples from subjects having no prostate cancer as training samples; and thereby evaluating as to the presence or absence of prostate cancer in vitro.

3. The method according to claim 1 , wherein the expression level of hsa-miR-1185-2-3p in the sample is measured by using a kit comprising a nucleic acid(s) that specifically binds to hsa-miR-1185-2-3p.

4. The method according to claim 3 , wherein the kit further comprises at least one nucleic acid capable of specifically binding to at least one polynucleotide selected from the following other prostate cancer markers: miR-197-5p, miR-6076, and/or miR-17-3p, miR-320b, miR-6819-5p, and miR-1228-5p.

5. The method according to claim 1 , wherein the expression level of hsa-miR-1185-2-3p in the sample is measured by using a device comprising a nucleic acid(s) that specifically binds to hsa-miR-1185-2-3p.

6. The method according to claim 5 , wherein the device further comprises at least one nucleic acid capable of specifically binding to at least one polynucleotide selected from the following other prostate cancer markers: miR-197-5p, miR-6076, and/or miR-17-3p, miR-320b, miR-6819-5p, and miR-1228-5p.

Assignees

• Toray Industries
• Nat Cancer Ct

Inventors

• Yoshimoto Makiko
• Sudo Hiroko
• Miyano Atsuko
• Kozono Satoko
• Ochiya Takahiro
• Fujimoto Hiroyuki
• URABE Fumihiko
• Matsuzaki Juntaro

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title